Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
LXRX closed down 22.6 percent on Friday, January 18, 2019, on 7.11 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The bears made the stock sink to a new 52-week low.
|Weak or Absent||Down||Down||Down|
|See historical LXRX trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Fell Below 20 DMA||Bearish||0.00%|
|Jan 18||Fell Below 50 DMA||Bearish||0.00%|
|Jan 18||MACD Bearish Centerline Cross||Bearish||0.00%|
|Jan 18||New 52 Week Closing Low||Bearish||0.00%|
|Jan 18||Expansion Breakdown||Bearish Swing Setup||0.00%|
|Jan 18||Gilligan's Island Buy Setup||Bullish Swing Setup||0.00%|
|Jan 18||Volume Surge||Other||0.00%|
|Jan 18||New 52 Week Low||Weakness||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more LXRX news...
|52 Week High||13.97|
|52 Week Low||5.29|
|200-Day Moving Average||9.7834|
|50-Day Moving Average||7.5306|
|20-Day Moving Average||6.9525|
|10-Day Moving Average||7.295|
|Average True Range||0.6132|
|Chandelier Exit (Long, 3 ATRs )||6.2404|
|Chandelier Exit (Short, 3 ATRs )||7.1296|
|Upper Bollinger Band||8.0109|
|Lower Bollinger Band||5.8941|
|Percent B (%b)||0.03|
|MACD Signal Line||-0.0956|
|Market Cap||631.06 Million|
|Num Shares||106 Million|
|Price-to-Earnings (P/E) Ratio||-4.48|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.48|
|Resistance 3 (R3)||7.42||6.86||7.22|
|Resistance 2 (R2)||6.86||6.47||6.89||7.14|
|Resistance 1 (R1)||6.41||6.24||6.64||6.47||7.05|
|Support 1 (S1)||5.40||5.46||5.63||5.46||4.87|
|Support 2 (S2)||4.84||5.23||4.87||4.78|
|Support 3 (S3)||4.39||4.84||4.70|
|Support 4 (S4)||4.45|